Small Pharma Inc. (DMTTF), a biotech company specializing in short-acting psychedelics, has just received final approval from the Supreme Court of British Columbia for its planned acquisition by clinical-stage biotech firm Cybin Inc. (CYBN). This arrangement, set to be executed as an all-share transaction, has been given the green light under Division 5 of Part 9 of BC’s Business Corporations Act.
With the final order in hand, as well as the necessary confirmations from both companies’ shareholders, the completion of the acquisition is imminent – subject to the satisfaction or waiver of customary closing conditions, including the final approval of the TSX Venture Exchange, where Small Pharma is traded. It is anticipated that the arrangement will officially close on or around October 23, 2023.
Once the acquisition is finalized, Small Pharma’s common shares will be delisted from the TSXV and removed from the OTCQB Venture Market. Consequently, the company will cease to be a reporting issuer in Canada.
Investors who may have missed out on the initial wave of cannabis investments are urged not to repeat that mistake. Cannabis stocks are now believed to have hit their floor and are on the cusp of unprecedented growth. To capitalize on this opportunity, consider joining Benzinga PotProfits. Michael Berger, a renowned expert in the field, provides sharp analysis, uncovering top cannabis stock opportunities and delivering timely updates. With a 4.5-star Marketfy rating, Benzinga PotProfits offers the potential for 10%+ returns in just 90 days. Secure your position in this thriving sector with a 30-day money-back guarantee. The time to invest is now, before the rest of the market catches on. Seize your profits with Benzinga. Click here now to learn more.
Photo: Benzinga edit with photo by Zita and Canadastock on Shutterstock.
